<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-INDINAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="INDINAVIR" rxcui="114289">
<ATC code="J05AE02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AR06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the indinavir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the medications together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-INDINAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="INDINAVIR" rxcui="114289">
<ATC code="J05AE02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="NEVIRAPINE" rxcui="53654">
<ATC code="J05AR05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the indinavir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the medications together.</COMMENT>
</INTERACTION>
</INTERACTIONS>
